Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes.


Journal

Environmental health and preventive medicine
ISSN: 1347-4715
Titre abrégé: Environ Health Prev Med
Pays: Japan
ID NLM: 9609642

Informations de publication

Date de publication:
23 Jul 2020
Historique:
received: 02 04 2020
accepted: 05 07 2020
entrez: 25 7 2020
pubmed: 25 7 2020
medline: 20 9 2020
Statut: epublish

Résumé

Various treatments for hepatocellular carcinoma (HCC) are utilized in clinical practice; however, the prognosis is still poor on account of high recurrence rates. DNA methylation levels of CpG islands around promoters (promoter CpGis) inversely regulate gene expression and closely involved in carcinogenesis. As a new strategy, several chemicals globally inhibiting DNA methylation have been developed aiming at reducing DNA methylation levels and maintaining the expression of tumor suppressor genes. On the other hand, since these drugs nonspecifically modify DNA methylation, they can cause serious adverse effects. In order to ameliorate the methods by targeting specific CpGs, information of cancer-related genes that are regulated by DNA methylation is required. We searched candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and which are involved in HCC cases. To do so, we first identified genes whose expression were changed in HCC by comparing gene expressions of 371 HCC tissues and 41 non-tumor tissues using the Cancer Genome Atlas (TCGA) database. The genes were further selected for poor prognosis by log-rank test of Kaplan-Meier plot and for cancer relevance by Pubmed search. Expression profiles of upregulated genes in HCC tissues were assessed by Gene Ontology (GO) analysis. Finally, using DNA methylation data of TCGA database, we selected genes whose promoter DNA methylation levels were inversely correlated with gene expression. We found 115 genes which were significantly up- or downregulated in HCC tissues and were associated with poor prognosis and cancer relevance. The upregulated genes were significantly enriched in cell division, cell cycle, and cell proliferation. Among the upregulated genes in HCC, we identified hypomethylation of CpGis around promoters of FANCB, KIF15, KIF4A, ERCC6L, and UBE2C. In addition, TCGA data showed that the tumor suppressor gene P16 is unexpectedly overexpressed in many types of cancers. We identified five candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and associate with cancer cases and poor prognosis in HCC. Modification of site-specific DNA methylation of these genes enables a different approach for HCC treatment with higher selectivity and lower adverse effects.

Sections du résumé

BACKGROUND BACKGROUND
Various treatments for hepatocellular carcinoma (HCC) are utilized in clinical practice; however, the prognosis is still poor on account of high recurrence rates. DNA methylation levels of CpG islands around promoters (promoter CpGis) inversely regulate gene expression and closely involved in carcinogenesis. As a new strategy, several chemicals globally inhibiting DNA methylation have been developed aiming at reducing DNA methylation levels and maintaining the expression of tumor suppressor genes. On the other hand, since these drugs nonspecifically modify DNA methylation, they can cause serious adverse effects. In order to ameliorate the methods by targeting specific CpGs, information of cancer-related genes that are regulated by DNA methylation is required.
METHODS METHODS
We searched candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and which are involved in HCC cases. To do so, we first identified genes whose expression were changed in HCC by comparing gene expressions of 371 HCC tissues and 41 non-tumor tissues using the Cancer Genome Atlas (TCGA) database. The genes were further selected for poor prognosis by log-rank test of Kaplan-Meier plot and for cancer relevance by Pubmed search. Expression profiles of upregulated genes in HCC tissues were assessed by Gene Ontology (GO) analysis. Finally, using DNA methylation data of TCGA database, we selected genes whose promoter DNA methylation levels were inversely correlated with gene expression.
RESULTS RESULTS
We found 115 genes which were significantly up- or downregulated in HCC tissues and were associated with poor prognosis and cancer relevance. The upregulated genes were significantly enriched in cell division, cell cycle, and cell proliferation. Among the upregulated genes in HCC, we identified hypomethylation of CpGis around promoters of FANCB, KIF15, KIF4A, ERCC6L, and UBE2C. In addition, TCGA data showed that the tumor suppressor gene P16 is unexpectedly overexpressed in many types of cancers.
CONCLUSIONS CONCLUSIONS
We identified five candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and associate with cancer cases and poor prognosis in HCC. Modification of site-specific DNA methylation of these genes enables a different approach for HCC treatment with higher selectivity and lower adverse effects.

Identifiants

pubmed: 32703154
doi: 10.1186/s12199-020-00871-8
pii: 10.1186/s12199-020-00871-8
pmc: PMC7376645
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31

Subventions

Organisme : Ministry of Education, Culture, Sports. Science and Technology of Japan
ID : 26293154

Références

Onco Targets Ther. 2010 Jun 24;3:1-13
pubmed: 20616953
Biol Open. 2016 Jun 15;5(6):866-74
pubmed: 27170255
Clin Chem. 2017 Mar;63(3):700-713
pubmed: 28007957
EBioMedicine. 2016 Jun;8:30-39
pubmed: 27428416
Anal Cell Pathol (Amst). 2020 Apr 3;2020:6403012
pubmed: 32318326
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D322-6
pubmed: 16381878
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Funct Integr Genomics. 2020 Mar;20(2):211-221
pubmed: 31456134
Nature. 2004 May 27;429(6990):457-63
pubmed: 15164071
J Korean Med Sci. 2010 Aug;25(8):1152-9
pubmed: 20676325
Oncogene. 2004 Aug 26;23(39):6621-9
pubmed: 15208666
Future Med Chem. 2016;8(4):463-89
pubmed: 26976726
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
FEBS Open Bio. 2018 May 30;8(7):1093-1103
pubmed: 29988590
Int J Cancer. 2007 Jul 1;121(1):33-8
pubmed: 17354233
Sci Rep. 2017 Jun 23;7(1):4148
pubmed: 28646197
Oncogene. 2011 May 5;30(18):2087-97
pubmed: 21297668
Cancer Rep Rev. 2018 Mar;2(2):
pubmed: 29951643
Oncol Lett. 2018 May;15(5):7941-7947
pubmed: 29725481
Oncotarget. 2017 Jun 27;8(26):42116-42124
pubmed: 28178669
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Biochimie. 2012 Nov;94(11):2219-30
pubmed: 22609632
Hepatology. 2015 Jun;61(6):1945-56
pubmed: 25645722
Nat Commun. 2017 Jul 11;8:16026
pubmed: 28695892
World J Hepatol. 2015 Nov 18;7(26):2648-63
pubmed: 26609342
Oncotarget. 2017 Jan 17;8(3):5629-5637
pubmed: 27895318
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Mol Cell. 2015 Nov 19;60(4):524-36
pubmed: 26590712
Cancer Res. 1995 Oct 15;55(20):4525-30
pubmed: 7553621
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2776-8
pubmed: 9096291
Genome Biol. 2018 Nov 6;19(1):187
pubmed: 30400938
Anticancer Res. 2018 Mar;38(3):1317-1325
pubmed: 29491055
Nat Rev Mol Cell Biol. 2018 Dec;19(12):774-790
pubmed: 30425324
Clin Cancer Res. 2007 Mar 15;13(6):1634-7
pubmed: 17363514
Oncol Lett. 2019 Jul;18(1):237-246
pubmed: 31289493
Hematology. 2019 Dec;24(1):507-515
pubmed: 31242832
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Sci. 2013 Jun;104(6):651-6
pubmed: 23438337
Int J Mol Sci. 2018 Apr 12;19(4):
pubmed: 29649096
Cell Physiol Biochem. 2018;51(1):1-10
pubmed: 30439711
J Pathol. 2012 Jan;226(2):352-64
pubmed: 21990031
Mol Cell Biol. 2004 Feb;24(3):1270-8
pubmed: 14729971
Hepatol Int. 2017 Jan;11(1):45-53
pubmed: 27271356
Int J Tuberc Lung Dis. 2018 Jun 1;22(6):617-621
pubmed: 29862944
Cancer Biol Ther. 2018 Mar 4;19(3):230-238
pubmed: 29303411
Genome Biol. 2015 Nov 23;16:252
pubmed: 26592237
Sci Rep. 2017 Jun 9;7(1):3123
pubmed: 28600574

Auteurs

Junya Matsushita (J)

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.
Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Takehiro Suzuki (T)

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.

Kazuyuki Okamura (K)

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.

Gaku Ichihara (G)

Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Keiko Nohara (K)

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan. keikon@nies.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH